MedX Health Launches SkinSecure™ to Bring Direct, Non-Invasive, Objective Biological Measurement to Skin Health Research
A cloud-based SaaS platform linking MedX’s native SIAscope imaging devices to CRO and sponsor workflows.
Mapping collagen, melanin and haemoglobin in skin in around 30 seconds, without any need for biopsy.
MedX Health Corp. (TSXV: MDX) today announced the commercial launch of SkinSecure™, a cloud-based SaaS platform that links the Company’s native SIAscope multi-spectral imaging devices directly to Contract Research Organization (CRO) workflows. SkinSecure™ maps collagen, melanin and hemoglobin in living skin in a single capture, giving skin trials immediate, objective biomarker data across multiple sites and multiple subjects, with instant shared access to every result. Built on MedX’s patented SIAscopy™ technology, which powers its FDA-approved DermSecure™ platform and backed by more than 30 years of peer-reviewed scientific heritage, SkinSecure™ fits directly into established trial protocols. For collagen endpoints, it offers an alternative to expensive, invasive punch biopsies.
"Medicine established objective ways to measure our major systems long ago - the ECG for the heart, the EEG for the brain, the blood panel for what flows between them,” said John Gevisser, Chief Executive Officer of MedX Health. “Each became a standard. But what about skin, the body's largest organ? We come at this challenge from first principles, and this gives us the method and the science to establish a new standard. It also enables us to track genuine biological change precisely over time and, uniquely, to measure collagen in absolute rather than relative or derivative terms."
